medcelerator · clinician one-pager
New Daily Pill for Moderate-to-Severe Psoriasis (Ages 12+)
Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis — 12 and older, at least 40 kg
FDA Approved · United States · September 7, 2026
Condition: Plaque Psoriasis
Who this is for
Icotyde (icotrokinra) is a once-daily pill for moderate to severe plaque psoriasis. The United States approved it for people 12 and older who weigh at least 40 kilograms. Health Canada is still reviewing it.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220149Orig1s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/icotyde-icotrokinra